Aldosterone and hypertension in the cardiometabolic syndrome

Journal of Clinical Hypertension

Volumn 10, Issue 2, 2008, Pages 94-96

  Stas, Sameer ^a,c,d   Whaley Connell, Adam T ^a,c,d   Sowers, James R ^a,b,c,d  

^a Department of Internal Medicine ^*  (Colombia)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

^d Harry S Truman VA Medical Center   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE;

BODY MASS; EDITORIAL; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ALDOSTERONE; BODY MASS INDEX; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; METABOLIC SYNDROME X; RISK FACTORS;

EID: 42049116590     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08082.x     Document Type: Editorial

References (22)

1. Brown C.D., Higgins M., Donato K.A., et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8(9):605- 619.
2. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245- 1250.
3. Stas S.N., El-Atat F.A., Sowers J.R. Pathogenesis of hypertension in diabetes. Rev Endocr Metab Disord. 2004;5(3):221- 225.
4. Sharma A.M. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44(1):12- 19.
5. Cooper S.A., Whaley-Connell A., Habibi J., et al. Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293(4):H2009- H2023.
6. Manrique C., Lastra G., Whaley-Connell A., et al. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2005;7(8):471- 476.
7. Milliez P., Girerd X., Plouin P.F., Et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243- 1248.
8. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48(2):239- 245.
9. Conn J.W. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med. 1965;273(21):1135- 1143.
10. Fallo F., Veglio F., Bertello C., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454- 459.
11. Fallo F., Della Mea P., Sonino N., et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20(8):855- 861.
12. Giacchetti G., Ronconi V., Turchi F., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25(1):177- 186.
13. Kraus D., Jáger J., Meier B., et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37(7):455- 459.
14. Fallo F., Federspil G., Veglio F., et al. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep. 2007;9(2):106- 111.
15. Ehrhart-Bornstein M., Arakelyan K., Krug A.W., et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30(4):865-870.
16. McFarlane S.I., Sowers J.R. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003;88(2):516- 523.
17. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312- 318.
18. Schmidt B.M., Sammer U., Fleischmann I., et al. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension. 2006;47(4):650- 655.
19. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940- 951.
20. Stas S., Whaley-Connell A., Habibi J., et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148(8):3773- 3780.
21. Sakai R.R., McEwen B.S., Fluharty S.J., et al. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 2000;57(4):1337- 1345.
22. Gomez-Sanchez E.P. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens. 2004;13(2):191- 196.